Cancer therapy with engineered monoclonal antibodies

Update on Cancer Therapeutics

Volumn 1, Issue 2, 2006, Pages 147-157

  Binyamin, Liat ^a   Borghaei, Hossein ^a   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ADCC; Bispecific antibodies; Cetuximab; Conjugated antibodies; Fc receptors; Herceptin; Immunotoxins; Monoclonal antibodies; Phage display; Rituximab; Single chains

Indexed keywords

ANTHRACYCLINE; AURISTATIN PE; BEVACIZUMAB; CALICHEAMICIN; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXOTOXIN; FLUOROURACIL; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IRINOTECAN; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; RADIOISOTOPE; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TRASTUZUMAB;

ANGIOGENESIS; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CANCER; BRONCHOSPASM; CANCER DIAGNOSIS; CANCER THERAPY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENGINEERING; FEVER; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MEDICAL TECHNOLOGY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RADIOIMMUNOASSAY; RASH; REVIEW; RIGOR; THROMBOCYTOPENIA; URTICARIA; VOMITING;

EID: 33746295382     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.05.002     Document Type: Review

References (107)

1. Veronese M.L., and O'Dwyer P.J. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 40 (2004) 1292-1301
2. Kohler G., and Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6 (1976) 511-519
3. Trail P.A., King H.D., and Dubowchik G.M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52 (2003) 328-337
4. Trikha M., Yan L., and Nakada M.T. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 13 (2002) 609-614
5. Zwick E., Bange J., and Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8 (2002) 17-23
6. Hicklin D.J., Witte L., Zhu Z., Liao F., Wu Y., Li Y., et al. Monoclonal antibody strategies to block angiogenesis. Drug Discov Today 6 (2001) 517-528
7. Benhar I., Azriel R., Nahary L., Shaky S., Berdichevsky Y., Tamarkin A., et al. Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria. J Mol Biol 301 (2000) 893-904
8. Hoogenboom H.R. Overview of antibody phage-display technology and its applications. Methods Mol Biol 178 (2002) 1-37
9. Worn A., and Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305 (2001) 989-1010
10. Irving R.A., Coia G., Roberts A., Nuttall S.D., and Hudson P.J. Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics. J Immunol Methods 248 (2001) 31-45
11. von Mehren M., Adams G.P., and Weiner L.M. Monoclonal antibody therapy for cancer. Annu Rev Med 54 (2003) 343-369
12. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., et al. Single-chain antigen-binding proteins. Science 242 (1988) 423-426
13. Yokota T., Milenic D.E., Whitlow M., and Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52 (1992) 3402-3408
14. Begent R.H., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2 (1996) 979-984
15. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D., et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58 (1998) 485-490
16. Reiter Y., and Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 16 (1998) 513-520
17. Brinkmann U., and Pastan I. Immunotoxins against cancer. Biochim Biophys Acta 1198 (1994) 27-45
18. Friedman P.N., Chace D.F., Trail P.A., and Siegall C.B. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J Immunol 150 (1993) 3054-3061
19. Kreitman R.J. Immunotoxins in cancer therapy. Curr Opin Immunol 11 (1999) 570-578
20. Reiter Y., Brinkmann U., Lee B., and Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 14 (1996) 1239-1245
21. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., and Hudson P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 248 (2001) 47-66
22. Pluckthun A., and Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3 (1997) 83-105
23. Le Gall F., Kipriyanov S.M., Moldenhauer G., and Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 453 (1999) 164-168
24. Hudson P.J. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 11 (1999) 548-557
25. Hudson P.J., and Kortt A.A. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231 (1999) 177-189
26. Adams G.P., Schier R., McCall A.M., Crawford R.S., Wolf E.J., Weiner L.M., et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77 (1998) 1405-1412
27. Bauer S., Renner C., Juwana J.P., Held G., Ohnesorge S., Gerlach K., et al. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res 59 (1999) 1961-1965
28. Raag R., and Whitlow M. Single-chain Fvs. Faseb J 9 (1995) 73-80
29. Milenic D.E., Yokota T., Filpula D.R., Finkelman M.A., Dodd S.W., Wood J.F., et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51 (1991) 6363-6371
30. Peipp M., and Valerius T. Bispecific antibodies targeting cancer cells. Biochem Soc Trans 30 (2002) 507-511
31. Kipriyanov S.M., Moldenhauer G., Strauss G., and Little M. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 77 (1998) 763-772
32. Xiong D., Xu Y., Liu H., Peng H., Shao X., Lai Z., et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 × anti-CD3 bispecific diabody. Cancer Lett 177 (2002) 29-39
33. Loffler A., Kufer P., Lutterbuse R., Zettl F., Daniel P.T., Schwenkenbecher J.M., et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95 (2000) 2098-2103
34. McCall A.M., Adams G.P., Amoroso A.R., Nielsen U.B., Zhang L., Horak E., et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 36 (1999) 433-445
35. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2 (2003) 52-62
36. Mirick G.R., Bradt B.M., Denardo S.J., and Denardo G.L. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 48 (2004) 251-257
37. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
38. Kim J.A. Targeted therapies for the treatment of cancer. Am J Surg 186 (2003) 264-268
39. Khazaeli M.B., Conry R.M., and LoBuglio A.F. Human immune response to monoclonal antibodies. J Immunother 15 (1994) 42-52
40. Gelderman K.A., Tomlinson S., Ross G.D., and Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25 (2004) 158-164
41. Glennie M.J., and van de Winkel J.G. Renaissance of cancer therapeutic antibodies. Drug Discov Today 8 (2003) 503-510
42. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
43. Houghton A.N., and Scheinberg D.A. Monoclonal antibody therapies-a 'constant' threat to cancer. Nat Med 6 (2000) 373-374
44. Weiner L.M., and Carter P. The rollercoaster ride to anti-cancer antibodies. Nat Biotechnol 21 (2003) 510-511
45. Steplewski Z., Lubeck M.D., and Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221 (1983) 865-867
46. Weiner G.J., and Link B.K. Monoclonal antibody therapy of B cell lymphoma. Exp Opin Biol Ther 4 (2004) 375-385
47. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
48. Heijnen I.A., and van de Winkel J.G. Human IgG Fc receptors. Int Rev Immunol 16 (1997) 29-55
49. Sulica A., Morel P., Metes D., and Herberman R.B. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 20 (2001) 371-414
50. Wallace M.E., and Smyth M.J. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin Immunopathol 27 (2005) 49-64
51. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3 (2002) 83-90
52. Smyth M.J., Thia K.Y., Cretney E., Kelly J.M., Snook M.B., Forbes C.A., et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 162 (1999) 6658-6662
53. Wallace M.E., and Smyth M.J. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin Immunopathol 27 (2005) 49-64
54. Presta L.G., Shields R.L., Namenuk A.K., Hong K., and Meng Y.G. Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30 (2002) 487-490
55. Martin W.L., West J., Anthony P., Gan L., and Bjorkman P.J. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 7 (2001) 867-877
56. Schmidt K.V., and Wood B.A. Trends in cancer therapy: role of monoclonal antibodies. Semin Oncol Nurs 19 (2003) 169-179
57. Farah R.A., Clinchy B., Herrera L., and Vitetta E.S. The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr 8 (1998) 321-356
58. Yarden Y., and Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 57 (1988) 443-478
59. Baselga J., Norton L., Masui H., Pandiella A., Coplan K., Miller Jr. W.H., et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85 (1993) 1327-1333
60. Cobleigh M., Vogel C., Tripathy D., Robert N., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
61. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C., Dantis L., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 (1996) 737-744
62. Slamon D., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
63. R (H) in HER2-everexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol (1999) 127a
64. R (trastuzumab). Eur J Cancer 37 (2001) S18-S24
65. Burstein H.J., Kuter I., Campos S.M., Gelman R.S., Tribou L., Parker L.M., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 (2001) 2722-2730
66. her2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16 (1998) 2659-2671
67. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995) 1311-1318
68. Waksal H.W. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 18 (1999) 427-436
69. Lockhart C., and Berlin J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32 (2005) 52-60
70. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
71. Foon K.A., Yang X.D., Weiner L.M., Belldegrun A.S., Figlin R.A., Crawford J., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58 (2004) 984-990
72. Yang X.D., Jia X.C., Corvalan J.R., Wang P., and Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 (2001) 17-23
73. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
74. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
75. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
76. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., White C.A., Liles T.M., Royston I., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3266-3274
77. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
78. Shan D., Ledbetter J.A., and Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48 (2000) 673-683
79. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly H., Ma D., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 (1998) 1927-1932
80. Czuczman M.S., Grillo-Lopez A.J., White C.A., Saleh M., Gordon L., LoBuglio A.F., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
81. Demidem A., Lam T., Alas S., Hariharan K., Hanna N., and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12 (1997) 177-186
82. Gribben J.G., Freedman A., Woo S.D., Blake K., Shu R.S., Freeman G., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78 (1991) 3275-3280
83. Byrd J.C., Waselenko J.K., Maneatis T.J., Murphy T., Ward F.T., Monahan B.P., et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17 (1999) 791-795
84. McLaughlin P., Grillo-Lopez A., Link B., Czuczman R.R.L., Williams M., Heyman M., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
85. Berinstein N., Grillo-Lopez A., White C., Bence-Bruckler I., Maloney D., Czuczman M., et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1988) 995-1001
86. Piro L., White C., Grillo-Lopez A., Janakiraman N., Saven A., Beck T., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 (1999) 619-621
87. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
88. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
89. Beerli R.R., Wels W., and Hynes N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 269 (1994) 23931-23936
90. Jannot C.B., Beerli R.R., Mason S., Gullick W.J., and Hynes N.E. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13 (1996) 275-282
91. Richardson J.H., Sodroski J.G., Waldmann T.A., and Marasco W.A. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci USA 92 (1995) 3137-3141
92. Marasco W.A., Chen S., Richardson J.H., Ramstedt U., and Jones S.D. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther 9 (1998) 1627-1642
93. Naito M., and Tsuruo T. Monoclonal antibodies to P-glycoprotein: preparation and applications to basic and clinical research. Methods Enzymol 292 (1998) 258-265
94. Kreitman R.J. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 5 (2003) 44-51
95. Niv R., Cohen C.J., Denkberg G., Segal D., and Reiter Y. Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins. Curr Pharm Biotechnol 2 (2001) 19-46
96. Pastan I., Chaudhary V., and FitzGerald D.J. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61 (1992) 331-354
97. Pastan I., and Kreitman R.J. Immunotoxins in cancer therapy. Curr Opin Investig Drugs 3 (2002) 1089-1091
98. Jain R.K. Delivery of molecular medicine to solid tumors. Science 271 (1996) 1079-1080
99. Niv R., Assaraf Y.G., Segal D., Pirak E., and Reiter Y. Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein. Int J Cancer 94 (2001) 864-872
100. Pastan I., Beers R., and Bera T.K. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 248 (2004) 503-518
101. Zein N., Sinha A.M., McGahren W.J., and Ellestad G.A. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240 (1988) 1198-1201
102. Gatto B. Monoclonal antibodies in cancer therapy. Curr Med Chem Anti-Cancer Agents 4 (2004) 411-414
103. Law C.L., Cerveny C.G., Gordon K.A., Klussman K., Mixan B.J., Chace D.F., et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10 (2004) 7842-7851
104. Boerman O.C., van Schaijk F.G., Oyen W.J., and Corstens F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44 (2003) 400-411
105. DeNardo S.J., DeNardo G.L., Brush J., and Carter P. Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. Hybridoma 18 (1999) 13-21
106. Milenic D.E., and Brechbiel M.W. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 3 (2004) 361-370
107. Goldenberg D.M. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52 (2003) 281-296